Rivastigmine tartrate
Rivastigmine tartrate (pronunciation: ri-vas-TIG-meen TAR-trate) is a pharmaceutical drug used primarily for the treatment of Alzheimer's disease and Parkinson's disease.
Etymology
The name "Rivastigmine" is derived from its chemical structure, which is a combination of "riva" from its developer Novartis' former name Rivapharm, and "stigmine" indicating its class of parasympathomimetic or cholinergic agents. The "tartrate" refers to the salt form of the drug, which is combined with tartaric acid to improve its stability and absorption.
Pharmacology
Rivastigmine tartrate is a type of drug known as a cholinesterase inhibitor. It works by increasing the levels of a certain substance (acetylcholine) in the brain, which can help reduce the symptoms of dementia in patients with Alzheimer's disease.
Usage
Rivastigmine tartrate is used to treat confusion (dementia) related to Alzheimer's disease and Parkinson's disease. It does not cure either of these diseases, but it may improve memory, awareness, and the ability to perform daily functions.
Side Effects
Common side effects of Rivastigmine tartrate include nausea, vomiting, loss of appetite, and weight loss. More serious side effects can include slow or irregular heartbeat, fainting, and seizures.
Related Terms
- Cholinesterase inhibitor
- Alzheimer's disease
- Parkinson's disease
- Dementia
- Novartis
- Pharmaceutical drug
External links
- Medical encyclopedia article on Rivastigmine tartrate
- Wikipedia's article - Rivastigmine tartrate
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski